ZK 157138
Latest Information Update: 19 Apr 2007
At a glance
- Originator Bayer HealthCare Pharmaceuticals
- Class Anticoagulants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 19 Apr 2007 Discontinued - Preclinical for Thrombosis in USA (unspecified route)
- 16 Jul 1997 No-Development-Reported for Thrombosis in USA (Unknown route)
- 23 Jan 1995 Preclinical development for Thrombosis in USA (Unknown route)